CD33 overactivation shifts SPP1-mediated microglial response from restorative (disease-associated microglia pathway) to destructive (excessive synapse engulfment and inflammatory cytokine release). CD33 antagonism converts SPP1 signaling toward neuroprotection by blocking the inhibitory ITIM domain signaling that normally suppresses microglial phagocytosis of amyloid plaques while promoting aberrant synapse elimination. Unlike TREM2 which requires agonism to enhance beneficial microglial functions, CD33 requires antagonism to remove the molecular brake on protective microglial responses. The mechanistic switch operates through CD33's competition with TREM2 for overlapping ligands including phosphatidylserine and APOE, where CD33 blockade shifts the balance toward TREM2-mediated neuroprotective signaling. SPP1 acts as the downstream effector whose cellular consequences depend on this CD33/TREM2 signaling balance - when CD33 is blocked, SPP1 promotes microglial transition to the beneficial DAM phenotype characterized by enhanced debris clearance and trophic factor release.

CD33 overactivation shifts SPP1-mediated microglial response from restorative (disease-associated microglia pathway) to destructive (excessive synapse engulfment and inflammatory cytokine release). CD33 antagonism converts SPP1 signaling toward neuroprotection by blocking the inhibitory ITIM domain signaling that normally suppresses microglial phagocytosis of amyloid plaques while promoting aberrant synapse elimination. Unlike TREM2 which requires agonism to enhance beneficial microglial functions, CD33 requires antagonism to remove the molecular brake on protective microglial responses. The mechanistic switch operates through CD33's competition with TREM2 for overlapping ligands including phosphatidylserine and APOE, where CD33 blockade shifts the balance toward TREM2-mediated neuroprotective signaling. SPP1 acts as the downstream effector whose cellular consequences depend on this CD33/TREM2 signaling balance - when CD33 is blocked, SPP1 promotes microglial transition to the beneficial DAM phenotype characterized by enhanced debris clearance and trophic factor release. This hypothesis leverages existing CD33 antagonist programs and anti-CD33 antibody platforms, creating a mechanistically distinct but complementary approach to the TREM2 agonist strategy. The intervention targets the same SPP1-mediated microglial state transition but through opposing modulation of an inhibitory rather than activating receptor. Decisive experiment: RNA-seq comparison of SPP1-treated CD33-blocked vs. control microglia in AD models to confirm that CD33 antagonism redirects SPP1 toward the same beneficial transcriptional program achieved by TREM2 agonism, validating convergent therapeutic mechanisms through divergent receptor modulation strategies.